{"disease":{"id":"tumors-harboring-ntrk-fusion","name":"tumors harboring ntrk fusion"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05192642","title":"A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice","phase":"","overall_status":"COMPLETED","enrollment_count":368,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02576431","title":"A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":215,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02637687","title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":154,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03215511","title":"A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT02122913","title":"A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05745623","title":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Beijing InnoCare Pharma Tech Co., Ltd.","has_results":false},{"nct_id":"NCT04771390","title":"Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07394374","title":"A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Cullgen (Shanghai),Inc","has_results":false},{"nct_id":"NCT04275960","title":"Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03206931","title":"Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03025360","title":"Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Bayer","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}